Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance
S Bagchi, R Yuan, EG Engleman - Annual Review of Pathology …, 2021 - annualreviews.org
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …
[HTML][HTML] A guide to cancer immunotherapy: from T cell basic science to clinical practice
AD Waldman, JM Fritz, MJ Lenardo - Nature Reviews Immunology, 2020 - nature.com
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …
central focus for engaging the immune system in the fight against cancer. Basic science …
[HTML][HTML] Emerging phagocytosis checkpoints in cancer immunotherapy
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase …
Background A phase 2 trial showed improved progression-free survival for atezolizumab
plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who …
plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who …
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-
PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients …
PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients …
Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …
[HTML][HTML] Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
[HTML][HTML] Emerging role of tumor cell plasticity in modifying therapeutic response
Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …
have proposed that acquisition of resistance may result from genetic mutations. However …
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …
elicited durable antitumor responses and long-term remissions in a subset of patients with a …